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Streptococcus suis (S.suis), a major swine pathogen, is also a severe threat to
human health. Infection with highly virulent strains of S. suis can cause human
Streptococcal toxic-shock-like syndrome (STSLS), which is associated with high serum
pro-inflammatory cytokine levels and a high mortality rate. Our previous study indicated
that highly virulent S. suis infection could activate the TREM-1 signaling pathway, which
promotes host clearance of S. suis during early infection. However, it remained to be
elicited whether TREM-1 signaling could be a target against STSLS in the presence
of antibiotic. In the present study, mice were infected with a highly virulent S. suis
strain and then treated with rTREM-1 (the recombinant extracellular domain of TREM-1)
to block TREM-1 signaling, antibiotics, both rTREM-1 and antibiotics, or PBS. The
survival rates, clinical signs, serum IL-1β and TNF-α levels, and serum bacterial loads
were evaluated. Treatment with rTREM-1 could aggravate the outcome of infection as
described previously. Although the conventional treatment with antibiotics contributed to
effective S. suis clearance, it did not improve survival significantly. In comparison, due to
the reduction of the exaggerated pro-inflammatory response, treatment combined with
rTREM-1 and antibiotics not only led to efficient bacterial clearance but also alleviated
inflammation. In conclusion, TREM-1 signaling contributed to severe inflammatory
response and benefited S. suis clearance. Therefore, blocking TREM-1 signaling could
still be a target for the treatment of STSLS in the presence of antibiotics.
Keywords: Streptococcus suis (S. suis), Streptococcal toxic-shock-like syndrome (STSLS), Triggering receptor
expressed on myeloid cells-1 (TREM-1), anti-inflammatory treatment, treatments targets
INTRODUCTION
Streptococcus suis (S. suis) is a major swine pathogen that is responsible for severe economic losses
in the porcine industry, and it is also a severe threat to human health (Segura, 2009;Wertheim et al.,
2009; Gottschalk et al., 2010b; Gottschalk, 2012). Since the first reported case of S. suis-induced
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meningitis in humans in Denmark in 1968, more than 1500
human infection cases have been reported in the world (Huong
et al., 2014). In addition, S. suis has also been identified as
the third most common cause of community-acquired bacterial
meningitis in Hong Kong and as the leading and second cause
of adult meningitis in Vietnam and in Thailand, respectively
(Suankratay et al., 2004; Mai et al., 2008; Segura, 2009). S. suis
infection in humans has remained sporadic for a long time and
mainly affects individuals in close contact with sick or carrier pigs
or pig-derived products (Huang et al., 2005; Smith et al., 2008;
Fowler et al., 2013). However, the large-scale outbreaks in China
in 1998 and 2005 (Tang et al., 2006; Yu et al., 2006) and a case of
human meningitis without a history of animal contact (Manzin
et al., 2008; Callejo et al., 2014) have modified perspectives
regarding the threat of S. suis to humans. Furthermore, human S.
suis isolates showed high degrees of adhesion to human intestinal
epithelial cells, suggesting that the pathogen should be considered
a food-borne pathogen (Ferrando et al., 2014). In addition, S.
suis infection is very dangerous for malignancy patients (Gomez-
Zorrilla et al., 2014) people with alcoholism (Nakayama et al.,
2013) and splenectomy patients (Gallagher, 2001; Tambyah and
Lee, 2001). It might also cause adverse clinical outcomes for
influenza-threatened people (Wang and Lu, 2008; Dang et al.,
2014).
S. suis infection in humans typically produces purulent
or nonpurulent meningitis, endocarditis, cellulitis, peritonitis,
rhabdomyolysis, arthritis, spondylodiscitis, pneumonia, uveitis,
endophthalmitis, and occasionally septic shock (Segura, 2009;
Choi et al., 2012; Zalas-Wiecek et al., 2013). Special attention
should be given to the largest recorded outbreak in 2005 in
China, in which 38 deaths were reported among 204 documented
human cases. Of the 38 deaths, 37 were associated with septic
shock, which was designated “Streptococcal toxic-shock-like
syndrome (STSLS)” (Tang et al., 2006). Notably, 63% of STSLS
patients died rapidly even after antimicrobial treatment (Lun
et al., 2007) and this disease was characterized by high serum
levels of IFN-γ, TNF-α, IL-8, IL-12, and IL-1β (Ye et al., 2009).
Studies using experimentally infected mice have demonstrated
that induction of high levels of systemic pro-inflammatory
cytokines plays an important role in sudden death or meningitis
(Lachance et al., 2014). In addition, the IFN-γ response was also
considered to be responsible for the high mortality rate of STSLS
(Lachance et al., 2013). These data suggested that inhibiting the
exaggerated inflammatory response may benefit the outcome of
the disease.
Triggering receptor expressed on myeloid cells-1 (TREM-1),
which belongs to the Ig superfamily, is an activating receptor
that is expressed on myeloid cells (Bouchon et al., 2000). It
can be induced at high levels on neutrophils and monocytes
and further amplifies Toll-like receptor (TLR)-initiated responses
against microbial challenges, potentiating the secretion of
proinflammatory cytokines with the help of the DAP12 adaptor
protein in response to bacterial and fungal infections (Bouchon
et al., 2001; Colonna and Facchetti, 2003; Dower et al., 2008).
Due to the key role of TREM-1 in amplifying the inflammatory
response, TREM-1 was identified as an essential regulator of
innate immunity in sepsis syndrome (Nathan and Ding, 2001)
and it was also confirmed to be an attractive target for the
treatment of septic shock (Gibot et al., 2006, 2007), sepsis
(Bouchon et al., 2001; Gibot et al., 2004; Wang et al., 2012; Pieters
et al., 2013; Van Bremen et al., 2013), inflammatory bowel disease
(Holden et al., 2009; Genua et al., 2014), chronic inflammatory
disorders (Schenk et al., 2007), autoimmune arthritis (Murakami
et al., 2009), corneal inflammation (Wu et al., 2011), and
hepatocellular chronic inflammation (Wu et al., 2012).
Our previous transcriptional analysis on swine spleen cells in
response to S. suis infection indicated that TREM-1 expression
was up-regulated and that a few pro-inflammatory genes were
highly expressed (Li et al., 2010). The TREM-1-mediated innate
immune response was confirmed to play an essential role
in the activation of neutrophils, which further benefited the
outcome of the infection by improving S. suis clearance (Yang
et al., 2015). However, the direct role of the TREM-1-mediated
innate immune response on STSLS is still unknown. Therefore,
the present study aimed to determine the contribution of
this signaling on severe inflammation. Because the TREM-1-
mediated innate immune response played a role during S. suis
clearance, in the present study, the recombinant extracellular
domain of TREM-1 (rTREM-1) was used to inhibit signaling in
the presence of antibiotics to evaluate the direct role of TREM-
1-mediated innate immune response on STSLS. In addition,
the present study also aimed to determine whether TREM-1




S. suis serotype 2 strain 05ZY (also known as SC-19) was isolated
from the brain of a diseased piglet during the outbreak of S.
suis diseases in China in 2005. The strain expresses muramidase-
released protein, extracellular protein factor, and suilysin and is
highly pathogenic to mice and pigs, causing STSLS (Zhang et al.,
2011, 2012).
The bacteria were cultured for 12 h in Tryptone Soya Broth
(BD) plus 10% bovine sera at 37◦C to reach stationary phase.
Then 500µl of the bacteria suspension was added into 50ml of
fresh Tryptone Soya Broth plus 10% bovine sera and cultured
for 4–6 h to reach log-phase. Then the bacteria suspension was
placed on ice to stop growth and then washed with PBS for two
times. Finally, the concentration of the bacteria suspension was
adjusted to 8× 108 CFU/ml for animal experiments. CFU per ml
values were further confirmed by spreading the serially diluted
bacteria suspension on Tryptone Soya Agar (BD) plates.
Preparation of rTREM-1
The recombinant extracellular domain of TREM-1 (rTREM-1)
was prepared according to the previous procedure (Yang et al.,
2015). Before rTREM-1 was used as the blocking agent, the
protein was confirmed to inhibit the enhanced inflammatory
response of platelets to LPS stimulation as described before (Yang
et al., 2015).
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Experimental Infection of Mice
The study was performed in strict accordance with the Guide for
the Care and Use of Laboratory Animals Monitoring Committee
of Hubei Province, China, and the protocol was approved by the
Committee on the Ethics of Animal Experiments at the College of
Veterinary Medicine, Huazhong Agricultural University (Permit
Number: 4200060000681). All efforts were made to minimize the
suffering of the animals used in the study.
Forty 6-week-old female C57BL/6 mice with similar body
weights were randomly divided into four groups with 10 mice
in each group. All mice were inoculated with an intraperitoneal
injection of 0.5ml of a S. suis strain (05ZYS) suspension at
8 × 108 CFU/ml. After 3 h, the four groups were treated by an
intraperitoneal injection of 0.5ml of PBS, ampicillin (2mg/ml),
rTREM-1(120µg/ml), or a combination of ampicillin (2mg/ml)
and rTREM-1 (120µg/ml). The mice were monitored three
times per day for 5 days for clinical signs and were assigned
clinical scores as described by Dominguez-Punaro et al. (2007).
Mice exhibiting extreme lethargy or neurological signs were
considered moribund and were humanely killed. The body
weight of each mouse was recorded every day. At the end of
the experiment, the surviving animals were sacrificed via carbon
dioxide inhalation.
Sixty 6-week-old female C57BL/6 mice with similar body
weights were randomly divided into five groups with 12 mice
in each group. Groups 1–4 were infected by an intraperitoneal
injection with 0.5ml of a S. suis strain (05ZYS) suspension
at 8 × 108 CFU/ml, and group 5 was mock infected with
PBS and served as a control. At 3 h post-infection, groups 1–4
were treated with an intraperitoneal injection of 0.5ml of PBS,
ampicillin (2mg/ml), rTREM-1(120µg/ml), or a combination
of ampicillin (2mg/ml) and rTREM-1(120µg/ml). Group 5 was
mock treated with PBS at that time point. At 3, 6, 9, and 24 h after
infection, three mice in each group were sacrificed via carbon
dioxide inhalation, and anticoagulated blood was collected via a
cardiac puncture. Fifty microliters of anticoagulated blood was
withdrawn for bacterial loading analysis. The remaining blood
was used to prepare plasma for the analysis of the IL-1β and
TNF-α concentrations.
Bacteria Load in Blood
The collected blood samples were serially diluted and then plated
on Tryptone Soya Agar (BD) plates to evaluate bacterial load.
Cytokine Measurements
The collected blood samples were serially diluted and then
were used to analyze the IL-1β and TNF-α concentrations
with ELISA kits according to the manufacturer’s protocols
(CityDakeweGroup, China). The samples and the known
standards were assayed in triplicate.
Histopathologic Evaluation
The lungs of mice at 6 h post-infection were fixed in 10% neutral
buffered formalin and routinely processed into paraffin. Sections
2 to 3mm in thickness were cut for hematoxylin and eosin
staining for histopathologic evaluation.
All lung samples were examined and scored by the technician
in National Key Laboratory of Agricultural Microbiology who
blinded to treatment and intervention. Five areas were randomly
selected from the every histopathologic section and then were
scored based on the severity and inflammation as following:
0 = Normal; 1 =Minimal hemorrhagic, consisting of occasional
degenerate neutrophils with extravasated erythrocytes and fibrin
and necrotic cellular debris; 2 = Mild hemorrhagic, consisting
of low numbers of degenerate neutrophils with extravasated
erythrocytes and fibrin and necrotic cellular debris; 3 =
Moderate hemorrhagic, consisting of moderate numbers of
degenerate neutrophils with extravasated erythrocytes and fibrin
and necrotic cellular debris; 4 = Severe hemorrhagic, consisting
of large numbers of degenerate neutrophils with abundant
extravasated erythrocytes and fibrin and necrotic cellular debris.
Statistical Analysis
Unless otherwise specified, the data were analyzed using two-
tailed, unpaired t-tests, and all assays were repeated at least
three times. The data were expressed as the means ± standard
deviations. For the animal infection experiments, survival was
analyzed using the log-rank test in GraphPad Prism 5. A
value of p < 0.05 was considered as the threshold for
significance.
RESULTS AND DISCUSSION
S. suis was recognized as a new emerging or old neglected
zoonotic pathogen (Gottschalk et al., 2010a). The infection can
induce high levels of inflammatory cytokines, an important
character of STSLS (Ye et al., 2009) which attracted researchers
to consider whether targeting the inflammatory response was
effective against STSLS (Dominguez-Punaro Mde et al., 2008;
Lagler et al., 2009; Lachance et al., 2013, 2014). Our previous
study indicated that TREM-1 regulated the innate immune
response and benefited clearance of S. suis (Yang et al., 2015).
Although direct targeting TREM-1 signaling was not effective,
it remained to be elicited whether the treatment was effective
when bacteria propagation was under the control. Therefore,
the present study used the recombinant extracellular domain
of TREM-1 (rTREM-1) as an inhibitor of TREM-1 signaling
to evaluate the direct contribution of TREM-1 signaling during
STSLS in the presence of antibiotics.
In the present study, mice infected with S. suis showed sudden
death and high fatality, similar to previous studies (Dominguez-
Punaro et al., 2007; Dominguez-Punaro Mde et al., 2008; Ye
et al., 2009). As described before, treatment with rTREM-1 alone
intensified rather than reducing the severity of the clinical signs,
which was also reflected by a change in body weight on days
1 and 2 post-infection (Figure 1). Furthermore, all of the mice
treated with rTREM-1 alone died within 3 days, while 40% of the
mice treated with PBS recovered from the infection (Figure 1).
These data indicated that treatment with rTREM-1 alone cannot
be used as a treatment strategy for STSLS (Bouchon et al., 2001;
Gibot et al., 2004; Wang et al., 2012).
Antibiotic treatment is typically administered during the
bacterial infection, although the treatment effectiveness on S. suis
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infection remains controversial. In the present study, treatment
with ampicillin at a given concentration could improve the
clinical manifestation in infected mice, which was reflected by a
quick recovery of body weight (Figure 1). However, 60% of mice
died during the infection despite receiving antibiotic treatment
(Figure 1), which was similar to the outcomes of the clinical
treatment of pigs and humans infected with highly virulent S.
suis. In contrast, 90% of mice that received a combination of
ampicillin and rTREM-1 recovered from the infection (Figure 1).
These data indicated that rTREM-1 acted synergistically with
the antibiotics to protect the mice against highly virulent S. suis
infection.
Because the TREM-1-mediated inflammatory response was
essential for S. suis clearance, the blockage of the signaling
by rTREM-1 would cause a high burden of bacterial load,
as described in our recent study (Figure 2). Undoubtedly,
administration of ampicillin could effectively control bacterial
growth when delivered with or without rTREM-1 (Figure 2).
However, inhibition of bacterial propagation alone cannot
significantly improve survival rates (Figure 1). In contrast,
blocking the TREM-1-mediated inflammatory response and
killing the bacteria at the same time had a significant effect against
S. suis infection.
Highly virulent S. suis can rapidly induce high levels of
inflammatory cytokines, resulting in a high fatality rate (Tang
et al., 2006; Dominguez-Punaro et al., 2007; Dominguez-Punaro
Mde et al., 2008; Ye et al., 2009). The correlation of severe
inflammation and a high mortality rate was further supported in
FIGURE 1 | Combined treatment with rTREM-1 and antibiotics protects
mice against S. suis infection. (A) Survival of mice infected with a highly
virulent S. suis strain. The mice were treated with PBS, rTREM-1, antibiotics,
or antibiotics+rTREM-1 at 3 h post-infection. (B) The daily body weight of mice
infected with highly virulent S. suis. “*” represents p < 0.05 for the selected
two groups.
this study. Serum levels of IL-1β and TNF-α reached the highest
levels 3–6 h post-infection before decreasing. The mice treated
with rTREM-1 maintained high levels of pro-inflammatory
cytokines even 9 h after infection (Figure 3). Treatment with
antibiotics alone could promote bacterial clearance and then
reduce the pro-inflammatory cytokine levels. However, the levels
of IL-1β and TNF-α in mice treated with both ampicillin and
rTREM-1 decreased very quickly (Figure 3), which indicated that
treatment with antibiotics alone was not enough to rapidly reduce
inflammation. This also indicated that enhancing bacterial death
FIGURE 2 | The kinetics of bacterial clearance from the blood of mice.
Mice were infected with a highly virulent S. suis strain and treated with PBS,
rTREM-1, antibiotics, or antibiotics+rTREM-1 at 3 h post-infection, and the
colony forming units (CFU) in blood were compared at 6, 9, and 24 h
post-infection. “*” represents p < 0.05 for the two selected groups, and “N”
represents no significant difference for the selected groups at the given
time-point.
FIGURE 3 | Kinetics of serum IL-1β (A) and TNF-α (B) in mice. Mice were
infected with a highly virulent S. suis strain and then treated with PBS,
rTREM-1, antibiotics, and antibiotics+rTREM-1 at 3 h post-infection, and the
serum TNF-α and IL-1β were determined with commercial ELISA kits. “*”
represents p < 0.05 for the two selected groups at the given time-point.
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FIGURE 4 | The histopathological study on lungs of mice infected with highly virulent S. suis strain for 6 h with different treatment. (A) The
histopathologic evaluation of lung of mice treated with PBS (b), rTREM-1(c), ampicillin (d), and a combination of ampicillin and rTREM-1 (e) at 6 h post infection with
highly virulent S. suis strain. The mock infected mice were served as a control (a). The red line represents 20µm. (B) The comparasion of histopathologic changes of
lung of mice infected with highly virulent S. suis strain with different treatment. Five areas were randomly selected from the every histopathologic section and then were
scored based on the severity and inflammation. Scores 0, 1, 2, 3, and 4 represent normal, minimal, mild, moderate, and severe histopathologic changes. “*”
represents p < 0.05 for the two selected groups.
by ampicillin and blockage of TREM-1-mediated response by
rTREM-1 at the same time could effectively protect the host
against epidemic S. suis infection.
The histopathological study of the lungs of mice infected with
a highly virulent strain for 6 h also indicated that treatment
with rTREM-1 could cause more severe lung inflammation
in comparison with PBS treatment (Figure 4). The treatment
with ampicillin alone alleviated the inflammation slightly, while
treatment with both ampicillin and rTREM-1 could alleviate
the inflammation significantly (Figure 4). These data indicated
that the TREM-1-mediated inflammatory response directly
contributed to STSLS in addition to contributing to S. suis
clearance.
Until now, TREM-1 was an attractive target for the treatment
of septic shock (Gibot et al., 2006, 2007), sepsis (Bouchon et al.,
2001; Gibot et al., 2004; Wang et al., 2012; Pieters et al., 2013; Van
Bremen et al., 2013), inflammatory bowel disease (Holden et al.,
2009; Genua et al., 2014) and chronic inflammatory disorders
(Schenk et al., 2007), autoimmune arthritis (Murakami et al.,
2009), corneal inflammation (Wu et al., 2011), and hepatocellular
chronic inflammation (Wu et al., 2012). However, in addition
to TREM-1 contributing to inflammation, TREM-1 also plays a
critical role in the clearance of Pseudomonas aeruginosa (Klesney-
Tait et al., 2013), pneumococci (Hommes et al., 2014), Kelbsiella
pneumoniae (Lin et al., 2014) and the highly virulent S. suis
(Yang et al., 2015). This might be the reason to explain that
blocking TREM-1 signaling alone cannot rescue the host from
these bacterial infections. In the present study, we found that
blocking TREM-1 signaling in the presence of antimicrobials
could significantly improve the survival of mice against S.
suis infection by efficient bacterial clearance and alleviated
severe inflammation. These results could further promoted the
researchers to evaluate the effect of blockage of TREM-1 signaling
in the presence of antimicrobials against severe inflammation
induced by Pseudomonas aeruginosa, pneumococci, andKelbsiella
pneumoniae.
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